Effects of fluvastatin therapy on lipids, antioxidants, oxidation of low density lipoproteins and trace metals

European Journal of Clinical Pharmacology

Volumn 53, Issue 1, 1997, Pages 65-69

  Leonhardt, W ^a   Kurktschiev, T ^a   Meissner, D ^b   Lattke, P ^a   Abletshauser, C ^c   Weidinger, G ^c   Jaross, W ^a   Hanefeld, M ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b Division of Operative Critical Care   (Germany)

^c NOVARTIS PHARMA GMBH   (Germany)

Author keywords

Tocopherol; Fluvastatin; LDL oxidation; Plasma trace metals

Indexed keywords

ALPHA TOCOPHEROL; CHOLESTEROL; COPPER; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MANGANESE; PLACEBO; RETINOL; SELENIUM; TRACE METAL; TRIACYLGLYCEROL; ZINC;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID COMPOSITION; LIPID OXIDATION; LIPOPROTEIN METABOLISM; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANTICHOLESTEREMIC AGENTS; ANTIOXIDANTS; DOUBLE-BLIND METHOD; FATTY ACIDS, MONOUNSATURATED; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; INDOLES; LIPID METABOLISM; LIPIDS; LIPOPROTEINS, LDL; MALE; METALS; MIDDLE AGED; VITAMIN A; VITAMIN E;

EID: 0030986505     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050338     Document Type: Article

References (31)

1. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL (1989) Beyond cholesterol. Modifications of low density lipoproteins that increase its atherogenicity. N Engl J Med 320: 915-924
2. Kontush A, Finckh B, Karten B, Kohlschutter A, Beisiegel U (1996) Antioxidant and prooxidant activity of alpha-tocopherol in human plasma and low density lipoprotein. J Lipid Res 37: 1436-1448
3. Frei B. Gaziano JM (1993) Content of antioxidants, preformed lipid hydroperoxides, and cholesterol as predictors of the susceptibility of human LDL to metal ion-dependent and ion-independent oxidation. J Lipid Res 34: 2135-2145
4. Leonhardt W, Hanefeld M, Müller G, Hora C, Meissner D, Lattke P, Paetzold A, Jaross W, Schroeder H-E (1996) Impact of concentrations of glycated hemoglobin, a-tocopherol, copper, and manganese on oxidation of low-density lipoproteins in patients with type I diabetes, type II diabetes and control persons. Clin Chim Acta 254: 173-186
5. Esterbauer H, Gebicky J, Puhl H, Jürgens G (1992) The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med 13: 341-390
6. Kleinveld HA, Hak-Lemmers HL, Stalenhoef AF, Demacker PN (1992) Improved measurement of low-density-lipoprotein susceptibility to copper-induced oxidation: application of a short procedure for isolating low-density lipoprotein. Clin Chem 38: 2066-2072
7. Croft KD, Williams P, Dimmitt S, Abuamsha R, Beilin LJ (1995) Oxidation of low-density lipoproteins: Effect of antioxidant content, fatty acid composition and intrinsic phospholipase activity on susceptibility to metal ion-induced oxidation. Biochim Biophys Acta 1254: 250-256
8. Esterbauer H, Striegl G, Puhl H, Rotheneder M (1989) Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun 6: 67-75
9. Regnström J, Strom K, Moldeus P, Nilsson J (1993) Analysis of lipoprotein diene formation in human serum exposed to copper. Free Radic Res Commun 19: 267-278
10. Gieseg SP, Esterbauer H (1994) Low density lipoprotein is saturable by pro-oxidant copper. FEBS Lett 343: 188-194
11. Salonen JT, Salonen R, Seppänen K, Kantola M, Suntioinen S, Korpela H (1991) Interactions of serum copper, selenium, and low density lipoprotein cholesterol in atherogenesis. BMJ 302: 756-760
12. Stalenhoef A (1994) Clinical implications of increased low-density lipoprotein oxidation in patients with hypercholesterolemia. Nutrition 10: 564-566
13. Stalenhoef A, Defesche J, Kleinveld H, Demacker P, Kastelein J (1994) Decreased resistance against ex vivo oxidation of LDL from patients with familial defective apolipoprotein B-100. Arterioscler Thromb 14: 489-493
14. Cominacini L, Pastorino AM, Garbin U, Campagnola M, Desantis A, Davoli A, Faccini G, Bertozzo L, Pasini F, Pasini AF, Locascio V (1994) The susceptibility of low-density lipoprotein to in vitro oxidation is increased in hypercholesterolemic patients. Nutrition 10: 527-531
15. Lavy A, Brook GJ, Dankner G, Ben-Amotz A, Aviram M (1991) Enhanced in vitro oxidation of plasma lipoproteins derived from hypercholesterolemic patients. Metabolism 40: 794-799
16. Napoli C, Postiglione A, Triggiani M, Corso G, Palumbo G, Carbone V, Ruocco A, Ambrosio G, Montefusco S, Malorni A, Condorelli M, Chiariello M (1995) Oxidative structural modifications of low density lipoprotein in homozygous familial hypercholesterolemia. Atherosclerosis 118: 259-273
17. Hoffman R, Brook GJ, Aviram M (1992) Hypolipidemic drugs reduce lipoprotein susceptibility to undergo lipid peroxidation: in vitro and ex vivo studies. Atherosclerosis 93: 105-113
18. Aviram M, Dankner G, Cogan U, Hochgraf E, Brook JG (1992) Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages: in vitro and in vivo studies. Metabolism 41: 229-235
19. Giroux LM, Davignon J, Naruszewicz M (1993) Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages. Biochim Biophys Acta 1165: 335-338
20. McDowell IFW, Brennan GM, Mceneny J, Young IS, Nicholls DP, McVeigh GE, Bruce I, Trimble ER, Johnston GD (1994) The effect of probucol and vitamin E treatment on the oxidation of low-density lipoprotein and forearm vascular responses in humans. Eur J Clin Invest 24: 759-765
21. Bredie SJH, Debruin TWA, Demacker PNM, Kastelein JJP, Stalenhoef AFH (1995) Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low density lipoprotein subfraction profile, and low-density lipoprotein oxidizability. Am J Cardiol 75: 348-353
22. Salonen R, Nyyssonen K, Porkkalasarataho E, Salonen JT (1995) The Kuopio Atherosclerosis Prevention Study (KAPS): effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. Am J Cardiol 76-C34-C39
23. Zhang A, Vertommen J, Vangaal L, Deleeuw I (1995) Effects of pravastatin on lipid levels, in vitro oxidizability of non-HDL lipoproteins and microalbuminuria in IDDM patients. Diabetes Res Clin Pract 29: 189-194
24. Anderson TJ, Meredith IT, Charbonneau F, Yeung AC, Frei B, Selwyn AP, Ganz P (1996) Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans. Circulation 93: 1647-1650
25. Lackner KJ, Mollers C, Leonhardt W, Hanefeld M, Abletshauser C, Schmitz G (1996) Effect of fluvastatin on antioxidants and oxidizability of LDL. 66th Congress of the European Atherosclerosis Society, Florence, July 13-17
26. Hussein O, Schlezinger S, Rosenblat M, Keidar S, Avirum M (1997) Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drus and its binding to the LDL. Atherosclerosis 128: 11-18
27. Puhl H, Waeg G, Esterbauer H (1994) Methods to determine oxidation of low-density lipoproteins. Oxygen radicals in biological systems. Methods Enzymol 233: 425-441
28. Leonhardt W, Pietzsch J, Nitzsche S (1994) Very-fast ultracentrifugation of human plasma lipoproteins - influence of the centrifugal field on lipoprotein composition. Clinica Chimica Acta 224: 21-32
29. Pietzsch J, Subal S, Nitzsche S, Leonhardt W, Schentke KU, Hanefeld M (1995) Very fast ultracentrifugation of serum lipoproteins: Influence on lipoprotein separation and composition. Biochim Biophys Acta 1254: 77-88
30. Sanz DC, Santa-Cruz MC (1986) Simultaneous measurement of retinol and α-tocopherol in human serum by high-performance liquid chromatography with ultraviolet detection. J Chromatogr 380: 140-144
31. Lowry OH, Rosebrough NJ, Farr AL, Randall AJ (1951) Protein measurement with Folin phenol reacent. J Biol Chem 193: 265-275